Aim: We analyzed the association between the modified albumin-bilirubin (mALBI) grade and therapeutic efficacy of atezolizumab plus bevacizumab (Atezo+Bev) for the treatment of unresectable hepatocellular carcinoma (u-HCC).
Methods: In this retrospective observational study, we included 71 u-HCC patients treated with Atezo+Bev between September 2020 and September 2021. Patients were grouped corresponding to the mALBI grade at the start of treatment (mALBI 1+2a or mALBI 2b+3) and analyzed for therapeutic effect and the transition rate to secondary treatment.
Results: According to the Response Evaluation Criteria in Solid Tumors, the overall response rate was significantly higher for the mALBI 1+2a group, than for the mALBI 2b+3 group, with 26.2% and 3.4%, respectively. The progression-free survival (PFS) was significantly longer in the mALBI 1+2a group (10.5 months) than in the mALBI 2b+3 group (3.0 months). In the multivariate analysis, an mALBI of 1+2a was found to be an independent factor of PFS. The rate of second-line treatment with multi-targeted agents was also significantly higher in the mALBI 1+2a group.
Conclusions: In real-world practice, Atezo+Bev treatment might have higher therapeutic efficacy in u-HCC patients with mALBI 1+2a.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939118 | PMC |
| http://dx.doi.org/10.1002/cam4.5145 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic Efficacy of the Albumin-Bilirubin Score and Treatment Outcomes in Hepatocellular Carcinoma: A Large-Scale, Multi-Center Real-World Database Study.
Liver Cancer
December 2024
Division of Liver Transplantation and Hepatobiliary Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Introduction: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality globally, with treatment outcomes closely tied to liver function. This study evaluates the prognostic utility of the albumin-bilirubin (ALBI) score compared to the traditional Child-Pugh (CP) grading, leveraging real-world evidence from a large-scale, multi-center database.
Methods: The Liver Cancer IN Korea (LINK) research network, a multi-center initiative, retrospectively collected electronic health records from three academic hospitals in South Korea, encompassing HCC patients diagnosed between 2015 and 2020.
Prognostic utility of the modified albumin-bilirubin score among patients undergoing curative-intent surgery for gallbladder cancer.
J Gastrointest Surg
December 2024
Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, United States. Electronic address:
Article Synopsis
- Gallbladder cancer (GBC) typically has a high risk of recurrence and poor outcomes even after surgery aimed at curing it, and the effectiveness of the modified ALBI (mALBI) score in predicting patient prognosis after surgery hadn’t been fully explored.
- A study examined the mALBI scores of 269 patients who had radical resection for GBC, finding that those with higher mALBI scores (grades 2b/3) had significantly worse 5-year overall survival (OS) and recurrence-free survival (RFS) compared to those with lower scores (grades 1/2a).
- The mALBI score may serve as a valuable tool for assessing liver function and predicting
Modified Albumin-Bilirubin Grade After Curative Treatment: Predicting the Risk of Late Intrahepatic Recurrence of Hepatocellular Carcinoma.
J Korean Med Sci
September 2024
Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Article Synopsis
- The study focused on identifying factors that predict late intrahepatic recurrence (IHR) of hepatocellular carcinoma (HCC) occurring over two years after curative treatment.
- It involved analysis of 2,304 patients who received curative treatment and were monitored for more than two years, revealing that 35.4% experienced late IHR.
- Key prognostic factors for late IHR included age, male sex, cirrhosis at diagnosis, type of treatment, and modified albumin-bilirubin (mALBI) grade measured at three and six months post-treatment.
Proton-beam Therapy for Locally Advanced Hepatocellular Carcinoma With Inferior Vena Cava Tumor Thrombus: Case Report.
In Vivo
June 2024
Department of Radiation Oncology, Shonan Kamakura General Hospital, Kamakura, Japan.
Background/aim: We report on a case of locally advanced hepatocellular carcinoma (HCC) accompanied by an inferior vena cava tumor thrombus (IVCTT), treated successfully with proton-beam therapy (PBT).
Case Report: A 63-year-old male presented with a primary, single HCC with IVCTT, without metastasis to the intrahepatic region, lymph nodes, or distant organs. The clinical staging was identified as T4N0M0 Stage IIIB.
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
Aliment Pharmacol Ther
July 2024
Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan.
Background: Atezolizumab plus bevacizumab (Atezo/Bev) is frequently selected as the primary systemic therapy for hepatocellular carcinoma (HCC).
Aims: To investigate the outcomes of patients with HCC treated with Atezo/Bev in a real-world setting based on whether they met the inclusion criteria for the phase 3 IMbrave150 trial.
Methods: A total of 936 patients were enrolled.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!